EW News and Press, Edwards Lifesciences Corporation From 01/26/21

Edwards Lifesciences (NYSE:EW) is scheduled to announce Q4 earnings results on Wednesday, January 27th, after market close.The consensus EPS Estimate is $0.53 (-63.7% Y/Y) and the consensus Revenue Estimate is $1.18B (+0.9% Y/Y).Over the last 2 years, EW has beaten EPS estimates 75% of the ti...

The medical device and equipment industry is expected to get a boost from an increase in elective surgeries as COVID-19 vaccines gradually control the virus’ spread this year. Because the demand for products used in cardiac surgeries is expected to increase as part of an overall resump...

After suffering supply chain breakdowns at the beginning of the COVID-19 pandemic, the medical devices segment is now on a strong path to recovery. The industry is expected to witness solid growth driven by rising health awareness, increasing elective surgeries, technological advancements, an...

Wedgewood Partners is a money manager founded in 1988 with the goal of providing investors with a superior approach to managing investment portfolios. For calendar 2020, our Composite (net) gained +32.1%. The S&P 500 Index gained +18.4%. The Russell 1000 Growth Index gained +38.5%...

Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021 PR Newswire IRVINE, Calif. , Jan. 13, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2020 after the...

Edwards Lifesciences is a quality name that sits at the tip of the spear in cardiovascular value procedure offerings. The company has remained resilient in the face of the pandemic, and is well positioned to benefit from the rebound in procedure deferrals. ROIC has consistently be...

A 20-year back-testing study of my annual index for US-listed quality stocks reveals remarkably consistent outperformance on a risk-adjusted basis: Up to 21.1% in average annualized returns, 4.8% annualized alpha, average max drawdown of 8.8%, average Sortino ratio of 3.89, and an ave...

The production of standard medical equipment and elective medical procedures is expected increase as COVID-19 vaccines gradually beat back the spread of the virus. With this, medical technology companies like Stryker (SYK), Edwards Lifesciences (EW), and Align Technology (ALGN) should witness...

Edwards Treats First Patient In U.S. Clinical Trial Evaluating Minimally Invasive Device For Mitral Valve Disease PR Newswire IRVINE, Calif. , Dec. 21, 2020 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW), today announced that the first patient has been trea...

Health Canada has approved expanded use of Edwards Lifesciences' ([[EW]] -0.6%) SAPIEN 3 and SAPIEN 3 Ultra transcatheter heart valves for the transfemoral treatment of patients diagnosed with severe symptomatic aortic stenosis (narrowing) who are at low risk for open-heart surgery.The compan...